BR112023003366A2 - Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso - Google Patents
Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de usoInfo
- Publication number
- BR112023003366A2 BR112023003366A2 BR112023003366A BR112023003366A BR112023003366A2 BR 112023003366 A2 BR112023003366 A2 BR 112023003366A2 BR 112023003366 A BR112023003366 A BR 112023003366A BR 112023003366 A BR112023003366 A BR 112023003366A BR 112023003366 A2 BR112023003366 A2 BR 112023003366A2
- Authority
- BR
- Brazil
- Prior art keywords
- binding molecules
- methods
- specific antigen
- hiv
- molecules targeting
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000008685 targeting Effects 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 108010039334 HIV Envelope Protein gp120 Proteins 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063070141P | 2020-08-25 | 2020-08-25 | |
US202163163713P | 2021-03-19 | 2021-03-19 | |
PCT/US2021/047165 WO2022046644A1 (en) | 2020-08-25 | 2021-08-23 | Multi-specific antigen binding molecules targeting hiv and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023003366A2 true BR112023003366A2 (pt) | 2023-05-09 |
Family
ID=77775012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023003366A BR112023003366A2 (pt) | 2020-08-25 | 2021-08-23 | Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230056252A1 (es) |
EP (1) | EP4204092A1 (es) |
JP (1) | JP2023539196A (es) |
KR (1) | KR20230054456A (es) |
CN (1) | CN116157416A (es) |
AU (1) | AU2021333577A1 (es) |
BR (1) | BR112023003366A2 (es) |
CA (1) | CA3187085A1 (es) |
CL (1) | CL2023000539A1 (es) |
CO (1) | CO2023002034A2 (es) |
CR (1) | CR20230101A (es) |
DO (1) | DOP2023000039A (es) |
IL (1) | IL300256A (es) |
MX (1) | MX2023002194A (es) |
PE (1) | PE20231105A1 (es) |
TW (1) | TW202348625A (es) |
WO (1) | WO2022046644A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021062119A1 (en) * | 2019-09-26 | 2021-04-01 | Regents Of The University Of Minnesota | Nk engager compounds that bind viral antigens and methods of use |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
JP4568896B2 (ja) | 2003-12-16 | 2010-10-27 | 財団法人くまもとテクノ産業財団 | 抗hiv抗体 |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
US8673307B1 (en) | 2009-03-09 | 2014-03-18 | The Rockefeller University | HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120 |
SI3260136T1 (sl) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa |
FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
EP2477658A2 (en) | 2009-09-16 | 2012-07-25 | Duke University | Hiv-1 antibodies |
CN103403026B (zh) | 2009-09-25 | 2016-05-11 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1中和抗体及其用途 |
WO2011046623A2 (en) | 2009-10-16 | 2011-04-21 | Duke University | Hiv-1 antibodies |
WO2011146891A2 (en) | 2010-05-21 | 2011-11-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins |
EP3556396B1 (en) | 2010-08-31 | 2022-04-20 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
WO2012154312A1 (en) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
MX358099B (es) | 2011-05-17 | 2018-08-06 | Univ Rockefeller | Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos. |
US9890207B2 (en) | 2011-07-25 | 2018-02-13 | California Institute Of Technology | Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120 |
US9493549B2 (en) | 2011-07-25 | 2016-11-15 | The Rockefeller University | Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth |
RU2624046C2 (ru) | 2011-11-07 | 2017-06-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз | Gp41-нейтрализующие антитела и их применение |
US9695230B2 (en) | 2011-12-08 | 2017-07-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein |
WO2013090644A2 (en) | 2011-12-13 | 2013-06-20 | California Institute Of Technology | Anti-hiv antibodies having increased potency and breadth |
EP2828294A1 (en) | 2012-03-23 | 2015-01-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 and their use |
WO2013163427A1 (en) * | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
WO2013192589A1 (en) | 2012-06-21 | 2013-12-27 | California Institute Of Technology | Antibodies targeting hiv escape mutants |
IL301018A (en) | 2012-10-18 | 2023-05-01 | Univ Rockefeller | Broad-spectrum neutralizing antibodies against the AIDS virus |
WO2014089152A1 (en) | 2012-12-04 | 2014-06-12 | University Of Maryland, Baltimore | Hiv-1 env-binding antibodies, fusion proteins, and methods of use |
WO2014159940A1 (en) * | 2013-03-14 | 2014-10-02 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
EP2968453B1 (en) | 2013-03-15 | 2019-12-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Stabilized single human cd4 domains and fusion proteins |
KR20230073341A (ko) | 2013-07-05 | 2023-05-25 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
US20160244510A1 (en) | 2013-09-27 | 2016-08-25 | Duke University | Human monoclonal antibodies |
EP3176185A1 (en) | 2013-11-04 | 2017-06-07 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
US10421803B2 (en) | 2014-01-31 | 2019-09-24 | The Rockefeller University | Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits |
US10093720B2 (en) * | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
US10676521B2 (en) | 2014-07-21 | 2020-06-09 | The Rockefeller University | Combination of broadly neutralizing HIV antibodies and viral inducers |
PE20171103A1 (es) | 2014-11-26 | 2017-08-07 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38 |
WO2016149710A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof |
US10344077B2 (en) | 2015-03-19 | 2019-07-09 | Duke University | HIV-1 neutralizing antibodies and uses thereof (V3 antibodies) |
SI3271389T1 (sl) | 2015-03-20 | 2020-09-30 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nevtralizirajoča protitelesa proti GP120 in njihova uporaba |
WO2016153572A1 (en) | 2015-03-25 | 2016-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
WO2016168758A1 (en) * | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
WO2016196975A1 (en) | 2015-06-03 | 2016-12-08 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
IL301140A (en) * | 2015-10-25 | 2023-05-01 | The Usa As Represented By The Sec Dep Of Health And Human Services | Trispecific and/or terrivalent binding proteins for the prevention or treatment of HIV infection |
EP4011911A1 (en) | 2015-11-03 | 2022-06-15 | The United States of America as represented by The Secretary Department of Health and Human Services | Neutralizing antibodies to hiv-1 gp41 and their use |
WO2017096221A1 (en) | 2015-12-02 | 2017-06-08 | The Rockefeller University | Bispecific anti-hiv broadly neutralizing antibodies |
EA201891186A1 (ru) | 2015-12-15 | 2018-12-28 | Джилид Сайэнс, Инк. | Антитела, нейтрализующие вирус иммунодефицита человека |
CN107022027B (zh) | 2016-02-02 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
CN107033241B (zh) | 2016-02-03 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
WO2018075564A1 (en) | 2016-10-17 | 2018-04-26 | University Of Maryland, College Park | Multispecific antibodies targeting human immunodeficiency virus and methods of using the same |
EP3562505A4 (en) | 2016-12-27 | 2020-11-11 | The Rockefeller University | HIGHLY NEUTRALIZING ANTI-HIV-1 ANTIBODIES AND THEIR USE PROCEDURE |
EP3642229A1 (en) | 2017-06-21 | 2020-04-29 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
WO2019226829A1 (en) | 2018-05-22 | 2019-11-28 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
CA3102859A1 (en) | 2018-07-03 | 2020-01-09 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
EP3830108A4 (en) | 2018-07-27 | 2022-08-10 | International AIDS Vaccine Initiative | MODIFIED ANTIBODIES TOWARDS HIV ENVs |
WO2020056145A1 (en) | 2018-09-14 | 2020-03-19 | The Rockefeller University | Anti-hiv antibody 10-1074 variants |
US20210355197A1 (en) | 2018-10-22 | 2021-11-18 | International Aids Vaccine Initiative | Anti-hiv antibodies |
-
2021
- 2021-08-23 PE PE2023000528A patent/PE20231105A1/es unknown
- 2021-08-23 AU AU2021333577A patent/AU2021333577A1/en active Pending
- 2021-08-23 CR CR20230101A patent/CR20230101A/es unknown
- 2021-08-23 CA CA3187085A patent/CA3187085A1/en active Pending
- 2021-08-23 IL IL300256A patent/IL300256A/en unknown
- 2021-08-23 MX MX2023002194A patent/MX2023002194A/es unknown
- 2021-08-23 US US17/409,260 patent/US20230056252A1/en active Pending
- 2021-08-23 BR BR112023003366A patent/BR112023003366A2/pt unknown
- 2021-08-23 CN CN202180053297.6A patent/CN116157416A/zh active Pending
- 2021-08-23 EP EP21770379.2A patent/EP4204092A1/en active Pending
- 2021-08-23 KR KR1020237010068A patent/KR20230054456A/ko active Search and Examination
- 2021-08-23 JP JP2023513114A patent/JP2023539196A/ja active Pending
- 2021-08-23 WO PCT/US2021/047165 patent/WO2022046644A1/en active Application Filing
- 2021-08-24 TW TW112133115A patent/TW202348625A/zh unknown
-
2023
- 2023-02-23 DO DO2023000039A patent/DOP2023000039A/es unknown
- 2023-02-23 CO CONC2023/0002034A patent/CO2023002034A2/es unknown
- 2023-02-23 CL CL2023000539A patent/CL2023000539A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2023000539A1 (es) | 2023-09-01 |
US20230056252A1 (en) | 2023-02-23 |
MX2023002194A (es) | 2023-03-03 |
CO2023002034A2 (es) | 2023-04-17 |
AU2021333577A1 (en) | 2023-03-30 |
JP2023539196A (ja) | 2023-09-13 |
CR20230101A (es) | 2023-04-28 |
WO2022046644A1 (en) | 2022-03-03 |
IL300256A (en) | 2023-03-01 |
PE20231105A1 (es) | 2023-07-19 |
DOP2023000039A (es) | 2023-03-23 |
KR20230054456A (ko) | 2023-04-24 |
TW202348625A (zh) | 2023-12-16 |
EP4204092A1 (en) | 2023-07-05 |
TW202233665A (zh) | 2022-09-01 |
CA3187085A1 (en) | 2022-03-03 |
CN116157416A (zh) | 2023-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018237148A8 (en) | Multispecific antibodies that target hiv gp120 and cd3 | |
EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
PE20170585A1 (es) | Moleculas de union a antigeno biespecificas activadoras de celulas t | |
CY1117036T1 (el) | Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων | |
EA202092907A1 (ru) | Мультиспецифические связывающие белки и их усовершенствования | |
BR112017014308A2 (pt) | anticorpos biespecíficos contra calicreína plasmática e fator xii | |
MX2022001942A (es) | Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. | |
BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
EA201991845A1 (ru) | Фармацевтические комбинации, содержащие антитело к ly75 | |
BR112023003366A2 (pt) | Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso | |
MX2023004275A (es) | Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos. | |
BR112022012474A2 (pt) | Anticorpo anti-lilrb1, fragmento de ligação ao antígeno do mesmo, composição farmacêutica que compreende os mesmos, uso do dito anticorpo para tratar ou prevenir um câncer, método de preparar o dito anticorpo, molécula de ácido nucleico e vetor e célula recombinantes. | |
MX2022009476A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
BR112022023117A2 (pt) | Constructos de anticorpos de domínio único neutralizantes de sars-cov2 | |
ZA202210626B (en) | Anti-cd137 constructs, multispecific antibody and uses thereof | |
PE20232050A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
CO2023018064A2 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
CL2023000084A1 (es) | Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas | |
BR112022026922A2 (pt) | Anticorpo anti-lilrb1 e usos do mesmo | |
AR127273A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos | |
BR112023020371A2 (pt) | Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer | |
WO2022204713A3 (en) | Antibodies to sars-cov-2 | |
BR112022021077A2 (pt) | Anticorpos humanizados antifator bb de complemento e uso dos mesmos | |
BR112022003635A2 (pt) | Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso |